Literature DB >> 25482949

Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.

Chiara Schiraldi1, Silvia Zappavigna, Antonella D' Agostino, Stefania Porto, Ornella Gaito, Sara Lusa, Monica Lamberti, Mario De Rosa, Giuseppe De Rosa, Michele Caraglia.   

Abstract

Time-lapse live cell imaging is a powerful tool for studying the responses of cells to drugs. Zoledronic acid (ZOL) is the most potent aminobiphosphonate able to induce cell growth inhibition at very low concentrations. The lack of clear evidence of ZOL-induced anti-cancer effects is likely due to its unfavorable pharmacokinetic profile. The use of nanotechnology-based formulations allows overcoming these limitations in ZOL pharmaco-distribution. Recently, stealth liposomes (LIPOs) and new self-assembly PEGylated nanoparticles (NPs) encapsulating ZOL were developed. Both the delivery systems showed promising anticancer activity in vitro and in vivo. In this work, we investigated the cytostatic effect of these novel formulations (LIPOs and NPs) compared with free ZOL on 2 different prostate cancer cell lines, PC 3 and DU 145 and on prostate epithelial primary cells EPN using time lapse video-microscopy (TLVM). In PC3 cells, free ZOL showed a significant anti-proliferative effect but this effect was lower than that induced by LIPOs and NPs encapsulating ZOL; moreover, LIPO-ZOL was more potent in inducing growth inhibition than NP-ZOL. On the other hand, LIPO-ZOL slightly enhanced the free ZOL activity on growth inhibition of DU 145, while the anti-proliferative effect of NP-ZOL was not statistically relevant. These novel formulations did not induce anti-proliferative effects on EPN cells. Finally, we evaluated cytotoxic effects on DU145 where, LIPO-ZOL induced the highest cytotoxicity compared with NP-ZOL and free ZOL. In conclusion, ZOL can be transformed in a powerful anticancer agent, if administered with nanotechnology-based formulations without damaging the healthy tissues.

Entities:  

Keywords:  CaP, calcium/phosphate; FPPS, farnesyl pirophosphate synthase; LIPO-ZOL, stealth liposomes encapsulating ZOL; LIPOs, stealth liposomes; NBPs, bisphosphonates; NPs, nanoparticles; TAM, tumor associated macrophages; TLVM, time lapse videomicroscopy; ZOL, zoledronic acid; blankLIPOs, empty pegylated liposomes; cell biology; cell toxicity; drug delivery; motility; nanotechnology; nanotoxicology; prostate cancer; self-assembly PEGylated nanoparticles; stealth liposomes; time lapse video-microscopy; zoledronic acid

Mesh:

Substances:

Year:  2014        PMID: 25482949      PMCID: PMC4623011          DOI: 10.4161/15384047.2014.955989

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  21 in total

Review 1.  Protein prenylation: genes, enzymes, targets, and functions.

Authors:  W R Schafer; J Rine
Journal:  Annu Rev Genet       Date:  1992       Impact factor: 16.830

Review 2.  Cell migration during morphogenesis.

Authors:  Andy Aman; Tatjana Piotrowski
Journal:  Dev Biol       Date:  2009-11-13       Impact factor: 3.582

3.  Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.

Authors:  Tianling Chen; James Berenson; Robert Vescio; Regina Swift; Alicia Gilchick; Susan Goodin; Patricia LoRusso; Peiming Ma; Christina Ravera; Fabienne Deckert; Horst Schran; John Seaman; Andrej Skerjanec
Journal:  J Clin Pharmacol       Date:  2002-11       Impact factor: 3.126

4.  Time-lapse microscopy approaches to track cell cycle and lineage progression at the single-cell level.

Authors:  Rachel J Errington; Sally C Chappell; Imtiaz A Khan; Nuria Marquez; Marie Wiltshire; Victoria D Griesdoorn; Paul J Smith
Journal:  Curr Protoc Cytom       Date:  2013-04

5.  In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.

Authors:  A Aparicio; A Gardner; Y Tu; A Savage; J Berenson; A Lichtenstein
Journal:  Leukemia       Date:  1998-02       Impact factor: 11.528

6.  The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.

Authors:  Andrej Skerjanec; James Berenson; ChyiHung Hsu; Pierre Major; Wilson H Miller; Christina Ravera; Horst Schran; John Seaman; Felix Waldmeier
Journal:  J Clin Pharmacol       Date:  2003-02       Impact factor: 3.126

7.  Bisphosphonate treatment inhibits the growth of prostate cancer cells.

Authors:  M V Lee; E M Fong; F R Singer; R S Guenette
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

8.  The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.

Authors:  Michele Caraglia; Anna Maria D'Alessandro; Monica Marra; Gaia Giuberti; Giovanni Vitale; Caterina Viscomi; Annamaria Colao; Salvatore Del Prete; Pierosandro Tagliaferri; Pierfrancesco Tassone; Alfredo Budillon; Salvatore Venuta; Alberto Abbruzzese
Journal:  Oncogene       Date:  2004-09-09       Impact factor: 9.867

9.  Time-lapse recordings of human corneal epithelial healing.

Authors:  Thorir Hardarson; Charles Hanson; Margareta Claesson; Ulf Stenevi
Journal:  Acta Ophthalmol Scand       Date:  2004-04

10.  Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

Authors:  P Tassone; P Tagliaferri; C Viscomi; C Palmieri; M Caraglia; A D'Alessandro; E Galea; A Goel; A Abbruzzese; C R Boland; S Venuta
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more
  5 in total

1.  Reverse Microemulsion-Based Synthesis of (Bis)phosphonate-Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acid-Calcium Complexes.

Authors:  Xu Li; Youssef W Naguib; Solange Valdes; Stephanie Hufnagel; Zhengrong Cui
Journal:  ACS Appl Mater Interfaces       Date:  2017-04-13       Impact factor: 9.229

2.  Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.

Authors:  Joanna Kopecka; Stefania Porto; Sara Lusa; Elena Gazzano; Giuseppina Salzano; Antonio Giordano; Vincenzo Desiderio; Dario Ghigo; Michele Caraglia; Giuseppe De Rosa; Chiara Riganti
Journal:  Oncotarget       Date:  2015-10-13

3.  Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.

Authors:  Joanna Kopecka; Stefania Porto; Sara Lusa; Elena Gazzano; Giuseppina Salzano; Martha Leonor Pinzòn-Daza; Antonio Giordano; Vincenzo Desiderio; Dario Ghigo; Giuseppe De Rosa; Michele Caraglia; Chiara Riganti
Journal:  Oncotarget       Date:  2016-04-12

4.  Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2+ γδ T cell cytotoxicity in a perforin-dependent manner.

Authors:  Daniel W Fowler; John Copier; Angus G Dalgleish; Mark D Bodman-Smith
Journal:  Cancer Immunol Immunother       Date:  2017-05-13       Impact factor: 6.968

Review 5.  Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.

Authors:  Lianwei Wang; Dengyang Fang; Jinming Xu; Runlan Luo
Journal:  BMC Cancer       Date:  2020-11-03       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.